Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Clough Capital Partners Discloses 5.24% Stake In Veracyte Inc. (VCYT)

Page 1 of 2

The Boston-based hedge fund Clough Capital Partners has disclosed a 5.24% passive stake of just under 1.44 million shares in Veracyte Inc. (NASDAQ:VCYT) through a 13G filing with the U.S. Securities and Exchange Commission. This marks an increase of 372,958 shares for the investment management firm run by Charles Clough since that firm’s most recent 13F filing for the reporting period of March 31. The transaction strengthens Clough Capital Partners’ position as the largest shareholder of Veracyte in our database, which it holds by a wide margin.


At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 144% and beating the market by more than 84 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise rather than large-cap stocks.

Clough Capital Partners was founded by Charles Clough and his partners, James Canty and Eric Brock, in 2000. The firm employs a global and theme-based investing approach, investing in securities all around the world. Clough had acted as the chief stock market strategist at Merrill Lynch before launching his own investment management firm and is generally known for his bearish bet against the U.S. economy in 2000, which didn’t please his employer, the self-proclaimed “bullish on America” brokerage firm. Nevertheless, Clough turned out to be right as the dot-com bubble burst soon enough. Clough’s track record has been impressive since leaving Merrill Lynch as well, as his hedge fund has delivered a cumulative return of 197% since its inception in 2000. This implies an average annualized return of 10.5% since its foundation. According to the most recent 13F filing, the public equity portfolio managed by Charles Clough is worth roughly $3.02 billion as of March 31.

Veracyte Inc. (NASDAQ:VCYT) is a diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. Specifically, the company focuses on the diseases that necessitate invasive procedures for an accurate diagnosis. The company’s stock has risen by over 10% since the beginning of the current year as the company has been quite successful in delivering strong financial performance accompanied by valuable and positive results from its diagnostic tests and studies. A huge part of Veracyte’s recent strong performance should be attributed to its President and CEO, Bonnie H. Anderson, who has been nominated as one of the 100 Most Creative People in Business 2015, a list published by Fast Company magazine. According to the above-mentioned magazine, Bonnie Anderson was selected and praised for “saving thousands of patients from the knife”, suggesting that her company’s diagnostic tests have proven to be reliable and trustworthy. Therefore, since the list mentioned above recognizes people across different industries who shape businesses into new directions, it’s quite clear that Veracyte is a very innovative and strong company with a bright future ahead.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!